ACD labs
ACD/Labs develops scientific software for chemical, biochemical, and pharmaceutical R&D, offering vendor-agnostic analytical data management and in silico molecular property prediction platforms (Spectrus, Percepta) plus standalone tools like ChemSketch and ACD/Name. The company serves 100% of the top 25 global pharma companies and 18 of 20 top universities, and was acquired by Revvity Signals in January 2026.
- Company typePrivate
- Founded1994
- HeadquartersToronto, Canada
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What ACD labs does
ACD/Labs (Advanced Chemistry Development, Inc.) develops and commercializes informatics software for chemical, biochemical, and pharmaceutical R&D. Founded in 1994 and headquartered in Toronto, Canada, the company built its portfolio over 30+ years around two flagship platforms: the Spectrus Platform for vendor-agnostic analytical data processing and knowledge management across LC/MS, NMR, GC/MS, HPLC, Raman, IR, and other techniques with native support for over 150 instrument data formats, and the Percepta Platform for in silico prediction of physicochemical, ADME, and toxicity properties built on 25+ years of curated experimental training data. Specialized modules address CMC decision support (Luminata), high-throughput experimentation (Katalyst D2D), metabolite identification (MetaSense), computer-assisted structure elucidation (Structure Elucidator Suite), NMR and MS processing, chromatography method development, and IUPAC nomenclature generation in 22 languages. Standalone products ChemSketch (over 2.5 million downloads) and ACD/Name extend reach to individual scientists and academic users.
The company monetizes through a hybrid model combining subscription and perpetual software licenses (e.g., ChemSketch at $320/year, ACD/Name at $475/year for self-serve), annual maintenance contracts, enterprise site-wide deployments via direct sales, and fee-based professional services for custom automation and digital transformation projects. Distribution is multi-channel: direct enterprise sales with consultation and demo requests, online e-commerce for self-serve purchasing, academic licensing with discounted pricing, and technology/integration partnerships with all major instrument vendors (Agilent, Thermo Fisher, Waters, Bruker, SCIEX, Shimadzu, PerkinElmer, JEOL), informatics platforms (Dassault BIOVIA, Schrödinger, Simulations Plus, Dotmatics, IDBS), and standards bodies (Allotrope Foundation, IUPAC, Pistoia Alliance). Customer concentration spans pharmaceutical/biotech R&D (primary), academic institutions, chemicals and materials science, flavors and fragrances, agrochemicals, forensics, environmental testing, food and beverage, and consumer goods, with 100% of the top 25 global pharma/biopharma and 18 of the top 20 universities using ACD/Labs software.
In November 2025, Revvity Inc. announced its intent to acquire ACD/Labs, and the transaction closed in mid-January 2026, integrating the company into Revvity Signals. Post-acquisition, ACD/Labs operates as part of Revvity Signals with bi-directional integration to the Revvity Signals Notebook ELN, expanded distribution through Revvity's enterprise sales force, and continued product investment including Version 2025 software releases that introduced AI-augmented reaction space exploration in Katalyst D2D and Japanese language IUPAC naming support.
ACD labs firmographics
Firmographics- Name
- ACD labs
- Legal name
- Advanced Chemistry Development, Inc.
- Website
- https://acdlabs.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- ACD/Labs develops scientific software for chemical, biochemical, and pharmaceutical R&D, offering vendor-agnostic analytical data management and in silico molecular property prediction platforms (Spectrus, Percepta) plus standalone tools like ChemSketch and ACD/Name. The company serves 100% of the top 25 global pharma companies and 18 of 20 top universities, and was acquired by Revvity Signals in January 2026.
- Ownership category
- akta.pro rank
ACD labs industry classification
Industry- Product category
- Chemistry Informatics Software
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Method Development & Validation (ICH/USP) (HLAGADAB), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where ACD labs is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
ACD labs business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Software Licenses: ACD/Labs generates revenue primarily through software licensing with both perpetual and subscription models. Customers can purchase software licenses with maintenance included or subscribe annually. Enterprise deployment options for site-wide licensing are available.
- Software Maintenance: Annual maintenance plans provide product enhancements, bug fixes, software updates, and access to technical support specialists. Maintenance is renewable annually.
- Professional Services: Custom consultation, digital transformation project support, and enterprise-wide automation solutions for analytical data management. Subject matter experts work with organizations to build bespoke solutions.
- Chemical Nomenclature Service: Fee-based expert service for generating IUPAC names for submitted chemical structures and name-to-structure requests.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | ChemSketch subscription license at $320.00 USD annually |
| Subscription | Annual | ACD/Name subscription license at $475.00 USD annually |
Go-to-market motion1 record
Distribution channels6 records
Marketing channels9 records
ACD labs product offering
Product offeringCore offering
ACD/Labs develops and commercializes informatics software for chemical, biochemical, and pharmaceutical R&D. Its Spectrus Platform handles vendor-agnostic, multi-technique analytical data (LC/MS, NMR, GC/MS, HPLC, Raman, IR), while the Percepta Platform delivers in silico predictions of physicochemical, ADME, and toxicity properties. Standalone tools include ChemSketch for chemical structure drawing and ACD/Name for IUPAC nomenclature generation in 22 languages.
Product overview
ACD/Labs offers scientific software for R&D across two main platforms. The Spectrus Platform provides standardized analytical data processing and knowledge management, supporting multi-technique data (LC/MS, NMR, GC/MS, chromatography, Raman, IR) with vendor-neutral support for over 150 data formats. Key applications include Luminata for CMC decision support, Katalyst D2D for high-throughput experimentation, and MetaSense for metabolite identification. Specialized modules handle NMR (NMR Workbook Suite, NMR Predictors), MS (MS Workbook Suite, MS Structure ID Suite, MS Fragmenter), chromatography (AutoChrom, Method Selection Suite), and structure elucidation (Structure Elucidator Suite). The Percepta Platform delivers molecular property prediction through the PhysChem Suite (logP, logD, pKa), ADME Suite (absorption, distribution, metabolism), and Tox Suite (toxicity endpoints). Standalone tools include ChemSketch for structure drawing (over 2.5 million downloads) and ACD/Name for IUPAC nomenclature. The portfolio serves pharmaceutical, biochemical, and chemical industries with enterprise automation, in silico predictions, and data-driven decision support.
Differentiator
Problem solved
Functional benefit
Brands
- Spectrus Platform: Enterprise platform for standardized analytical data processing and knowledge management
- Percepta Platform
- ChemSketch
- Name
Products and services
- Spectrus Platform
- Percepta Platform
- ChemSketch
- ACD/Name
- Katalyst D2D
- Luminata
- MetaSense
- Structure Elucidator Suite
Quantifiable outcome
- Reduced data analysis cycle time from more than a week to less than a day
- +3 more outcomes
Companies that use ACD labs
Customer profileNamed customers8 records
Segments11 records
Ideal customer profiles3 records
ACD labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability6 records
Feature11 records
ACD labs partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core.
- Revvity SignalscoreACD/Labs was acquired by Revvity Signals in January 2026 to expand Revvity's Signals software capabilities and enhance research informatics offerings. The acquisition integrates ACD/Labs' analytical and molecular design tools into Revvity's platform for pharmaceutical and material sciences workflows.
- AgilentcoreEquipment and instrument manufacturer partnership for data format support and integration with Spectrus Platform.
- Thermo Fisher ScientificcoreEquipment and instrument manufacturer partnership for data format support including Xcalibur, Chromeleon, and Atlas formats.
- WaterscoreEquipment and instrument manufacturer partnership for Empower, MassLynx, and UNIFI data format support.
- BrukercoreEquipment and instrument manufacturer partnership for Compass and NMR data format support.
- SCIEXcoreEquipment and instrument manufacturer partnership for Analyst data format support for LC/MS workflows.
- ShimadzucoreEquipment and instrument manufacturer partnership for LabSolutions CDS and LCMS data format support.
- PerkinElmercoreEquipment and instrument manufacturer partnership for TotalChrom and TOFData format support.
- JEOLcoreEquipment and instrument manufacturer partnership for NMR and MS data format support.
- Allotrope FoundationcoreStandards organization partnership for Allotrope Framework data standard support. ACD/Labs is a member of Allotrope Partner Network.
- IUPACcoreStandards organization partnership for JCAMP data format and nomenclature rule implementation.
Scale indicators15 records
Recent moves6 records
Expansion highlights6 records
ACD labs competitors and assessment
Company assessmentDirect peers
- Simulations Plus: Simulations Plus provides ADME-Tox modeling and physiologically-based pharmacokinetic (PBPK) simulation software. ACD/Labs is an explicit integration partner for ADME-Tox modeling, and the companies directly overlap in predicted ADME/Tox endpoints for pharma R&D.
- IDBS: IDBS delivers cloud and on-premise R&D informatics including the BioBook ELN referenced as an ACD/Labs integration partner. Comparable as a life-sciences-focused informatics platform serving pharma R&D with structured experimental data capture and workflow tools.
- Dotmatics: Dotmatics provides a scientific R&D informatics platform spanning ELN, LIMS, data management, and registration. ACD/Labs already integrates with the Dotmatics Registration Data Hub via Open Database Connectivity, indicating direct overlap in pharma/biopharma analytical data and registration workflows.
- OpenEye Scientific (Cadence Molecular Sciences): OpenEye/Cadence Molecular Sciences delivers molecular property prediction, cheminformatics, and structure-based design tools for pharma R&D. Directly comparable to ACD/Labs' Percepta Platform in molecular property and ADME prediction from chemical structure.
- ChemAxon: ChemAxon offers chemistry-focused informatics including structure drawing, nomenclature, and chemical intelligence toolkits. Directly comparable to ACD/Labs' ChemSketch and ACD/Name offerings in chemical structure handling and IUPAC naming.
- Schrödinger: Schrödinger provides computational chemistry and molecular simulation software for drug discovery. ACD/Labs lists Schrödinger as a computational chemistry integration partner, indicating overlap in molecular property prediction and drug discovery workflows targeting pharma/biotech R&D.
Others
- TIBCO Spotfire: Spotfire provides analytics and data visualization software used widely in pharma R&D. ACD/Labs integrates with Spotfire for viewing Katalyst, Luminata, and MetaSense data, positioning Spotfire as an adjacent analytics consumer rather than direct competition.
Emerging players
- Certara: Certara provides model-informed drug development software including PBPK, QSP, and regulatory submission tooling. Partial overlap with ACD/Labs' regulatory enablement and ADME prediction use cases, though Certara focuses on clinical/regulatory translation rather than analytical chemistry.
Broad incumbents
- Revvity Signals: Revvity Signals (the new parent of ACD/Labs) provides broader lab informatics and Signals software suite for pharma and material sciences. Now the parent company, but functions as the broader incumbent whose platform ACD/Labs' analytical tools are being integrated into.
- Dassault Systèmes BIOVIA: BIOVIA provides broad scientific informatics including computational chemistry, ELN, LIMS, and predictive sciences. ACD/Labs already partners with BIOVIA for DRAW file format compatibility. Overlaps with ACD/Labs in molecular property prediction and analytical data, but operates at much larger scale with a broader portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
ACD labs social profiles
Digital presenceACD labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
ACD labs leadership team
Management profileNumber of profiles
Profiles2 records
ACD labs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ACD labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ACD labs
What does ACD labs do?
ACD/Labs develops and commercializes informatics software for chemical, biochemical, and pharmaceutical R&D. Its Spectrus Platform handles vendor-agnostic, multi-technique analytical data (LC/MS, NMR, GC/MS, HPLC, Raman, IR), while the Percepta Platform delivers in silico predictions of physicochemical, ADME, and toxicity properties. Standalone tools include ChemSketch for chemical structure drawing and ACD/Name for IUPAC nomenclature generation in 22 languages.
Is ACD labs a public or private company?
ACD labs is a private company. It is classified as corporate owned and is currently acquired.
When was ACD labs founded?
ACD labs was founded in 1994. It employs 51 to 100 people.
Where is ACD labs based?
ACD labs is headquartered in Toronto, Canada, in the North America region.
How does ACD labs make money?
Four revenue lines are on record. Software Licenses are the primary driver. The others are software Maintenance, professional Services and chemical Nomenclature Service.
Who are ACD labs's main competitors?
Direct peers on record are Simulations Plus, IDBS, Dotmatics, OpenEye Scientific (Cadence Molecular Sciences), ChemAxon and Schrödinger. TIBCO Spotfire is listed as an others. Certara is listed as an emerging player. Broad incumbents are Revvity Signals and Dassault Systèmes BIOVIA.
Does ACD labs have an API?
No public API is recorded for ACD labs.
What industry is ACD labs in?
ACD labs's product category is Chemistry Informatics Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGADAB, Method Development & Validation (ICH/USP). Its NAICS code is 5417 and its SIC code is 7372.